Logo (Logo)
Pregabalin Capsule
Product Images NDC 68788-8667
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 68788-8667). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Preferred Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Pregabalinfigure1 (Pregabalinfigure1)
A line chart showing the percent of patients improved versus percent improvement in pain from baseline. The chart compares four groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, Pregabalin 25 mg three times a day, and placebo, indicating varying efficacy levels.*
Pregabalinfigure10 (Pregabalinfigure10)
A survival curve chart comparing the estimated percentage of subjects without LTR over a 180-day period between Pregabalin and placebo groups. The x-axis represents days, and the y-axis shows the estimated percentage of subjects without LTR, with Pregabalin showing a higher percentage over time compared to placebo.*
Pregabalinfigure11 (Pregabalinfigure11)
A line graph comparing the percentage of subjects improved from baseline to Week 12 as measured by LOCF for Pregabalin versus placebo. The x-axis shows percent improvement ranging from 0 to 100, and the y-axis shows the percent of subjects improved. Pregabalin has a higher percentage of subjects improved across the improvement levels compared to placebo, which has a consistently lower curve.*
Pregabalinfigure12 (Pregabalinfigure12)
A line graph depicting the percent of subjects improved over time from baseline to week 16. The x-axis represents the percent improved from baseline to week 16 BOCF, ranging from 0 to 100. The y-axis shows the percent of subjects improved, ranging from 0 to 100%. Two lines are displayed: one solid line for Pregabalin and one dotted line for Placebo, illustrating the comparative improvement rates over the study period.*
Pregabalinfigure2 (Pregabalinfigure2)
A line graph comparing percent improvement in pain from baseline against the percent of patients improved, showing two lines representing Pregabalin 100 mg three times a day and Placebo. The x-axis is labeled 'Percent Improvement in Pain from Baseline' from 0 to 100, and the y-axis is labeled 'Percent of Patients Improved' from 0 to 100.*
Pregabalinfigure3 (Pregabalinfigure3)
A line graph depicting percent of patients improved relative to percent improvement in pain from baseline. The graph compares responses for Pregabalin at doses of 75 mg, 150 mg, and 300 mg taken two times a day, along with a placebo group.*
Pregabalinfigure4 (Pregabalinfigure4)
A line graph showing the percent of patients improved versus percent improvement in pain from baseline. It compares three groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo, illustrating differences in patient improvement across treatment regimens.*
Pregabalinfigure5 (Pregabalinfigure5)
A line graph showing the percent of patients improved versus percent improvement in pain from baseline for Pregabalin 50 mg and 100 mg taken three times a day compared to placebo. The graph tracks patient improvement percentages along the x-axis from 0% to 100% and the y-axis represents the percent of patients improved from 0% to 100%.*
Pregabalinfigure6 (Pregabalinfigure6)
This image is a bar chart showing responder rates (%) from two clinical studies, labeled Study E1 and Study E3. The x-axis lists different treatments including placebo, doses of 600 mg/day, and 150 mg, while the y-axis measures the percentage of responders. The chart compares these treatment groups and indicates statistical significance against placebo.*
Pregabalinfigure7 (Pregabalinfigure7)
A line graph illustrating the median percentage change from baseline in seizure reduction by dose (mg/day) across four studies comparing once daily (BID) and three times daily (TID) dosing regimens of Pregabalin. The p-values indicating statistical significance are shown for relevant data points.*
Pregabalinfigure9 (Pregabalinfigure9)
A line graph illustrating the percent of patients improved on the y-axis against percent improvement in pain from baseline on the x-axis. Four lines compare Pregabalin daily doses of 600 mg, 450 mg, 300 mg, and placebo, showing varying improvement percentages across the pain improvement range.*
Pregabalinstructure (Pregabalinstructure)
Chemical structure of pregabalin, featuring its molecular arrangement with labeled functional groups including an amino group, carboxyl group, and alkyl side chains, representing the active ingredient in this prescription drug.*
Pregabalin Capsules 150mg (Pregablin Capsules 100 Container 60)
Pregabalin Capsules 150 mg label from Preferred Pharmaceuticals Inc. The label states the product is a generic for Lyrica, with each capsule containing 150 mg pregabalin. It includes storage instructions to keep the medication at 20° to 25°C, a caution about federal law prohibiting transfer, and dosage directions in English and Spanish. Manufacturer is listed as Hetero Labs Limited. Several fields for lot number, batch number, and expiration date are present but not filled in.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
